Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 4
2002 37
2003 79
2004 135
2005 120
2006 59
2007 35
2008 34
2009 14
2010 24
2011 13
2012 21
2013 11
2014 9
2015 6
2016 8
2017 6
2018 4
2019 2
2020 2
2021 3
2022 2
2023 1
2024 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

610 results

Results by year

Filters applied: . Clear all
Page 1
Ximelagatran.
Choudhury A, Goyal D, Lip GY. Choudhury A, et al. Drugs Today (Barc). 2006 Jan;42(1):3-19. doi: 10.1358/dot.2006.42.1.893611. Drugs Today (Barc). 2006. PMID: 16511607 Review.
Double-blind trials have also revealed the efficacy of ximelagatran in the secondary prevention of venous thromboembolism and shown the agent to be as effective as enoxaparin/warfarin in treating patients with acute deep vein thrombosis. Adverse effects with ximelagatra
Double-blind trials have also revealed the efficacy of ximelagatran in the secondary prevention of venous thromboembolism and shown t …
Ximelagatran in orthopaedic surgery.
Eriksson B. Eriksson B. Pathophysiol Haemost Thromb. 2005;34 Suppl 1:10-7. doi: 10.1159/000083079. Pathophysiol Haemost Thromb. 2005. PMID: 15812199 Review.
In METHRO II, immediate pre-operative-initiated s.c. melagatran followed by post-operative ximelagatran dose-dependently reduced VTE, with the highest dose (melagatran 3 mg/ximelagatran 24 mg twice daily) associated with a significantly reduced incidence of VTE comp …
In METHRO II, immediate pre-operative-initiated s.c. melagatran followed by post-operative ximelagatran dose-dependently reduced VTE, …
Ximelagatran: a new oral anticoagulant.
Hrebickova L, Nawarskas JJ, Anderson JR. Hrebickova L, et al. Heart Dis. 2003 Nov-Dec;5(6):397-408. doi: 10.1097/01.hdx.0000099777.39577.e8. Heart Dis. 2003. PMID: 14633322 Review.
Ximelagatran has also been demonstrated to cause transient increases in liver enzymes, the significance of which will need to be addressed in ongoing phase 3 studies. Should ongoing trials prove ximelagatran to have at least similar therapeutic efficacy and safety a
Ximelagatran has also been demonstrated to cause transient increases in liver enzymes, the significance of which will need to be addr
Ximelagatran--a promising new drug in thromboembolic disorders.
Petersen P. Petersen P. Curr Pharm Des. 2005;11(4):527-38. doi: 10.2174/1381612053382016. Curr Pharm Des. 2005. PMID: 15725069 Review.
Ximelagatran is an oral direct thrombin inhibitor (DTI), the active form of which is melagatran. ...Oral ximelagatran dosing not only inhibits thrombin activity rapidly, competitively, and potently, but also delays and suppresses thrombin generation. ...
Ximelagatran is an oral direct thrombin inhibitor (DTI), the active form of which is melagatran. ...Oral ximelagatran dosing n
Ximelagatran: direct thrombin inhibitor.
Ho SJ, Brighton TA. Ho SJ, et al. Vasc Health Risk Manag. 2006;2(1):49-58. doi: 10.2147/vhrm.2006.2.1.49. Vasc Health Risk Manag. 2006. PMID: 17319469 Free PMC article. Review.
As an oral agent, ximelagatran has a number of desirable properties including a rapid onset of action, fixed dosing, stable absorption, apparent low potential for medication interactions, and no requirement for monitoring of drug levels or dose adjustment. ...Clinical stud …
As an oral agent, ximelagatran has a number of desirable properties including a rapid onset of action, fixed dosing, stable absorptio …
Ximelagatran: a new oral anticoagulant.
Francis CW. Francis CW. Best Pract Res Clin Haematol. 2004 Mar;17(1):139-52. doi: 10.1016/j.beha.2004.03.005. Best Pract Res Clin Haematol. 2004. PMID: 15171963 Review.
Vitamin K antagonists are effective oral anticoagulants, but they have limitations related to a narrow therapeutic range, food and drug interactions, slow onset of action and the need for routine coagulation monitoring. Ximelagatran is a promising new oral anticoagulant un …
Vitamin K antagonists are effective oral anticoagulants, but they have limitations related to a narrow therapeutic range, food and drug inte …
Ximelagatran: the first oral direct thrombin inhibitor.
Crowther MA, Weitz JI. Crowther MA, et al. Expert Opin Investig Drugs. 2004 Apr;13(4):403-13. doi: 10.1517/13543784.13.4.403. Expert Opin Investig Drugs. 2004. PMID: 15102589 Review.
Since it produces a predictable anticoagulant response, ximelagatran does not require coagulation monitoring. Phase III clinical trials have evaluated the efficacy and safety of ximelagatran for the prevention and treatment of venous thromboembolism and for the prev …
Since it produces a predictable anticoagulant response, ximelagatran does not require coagulation monitoring. Phase III clinical tria …
Ximelagatran--promises and concerns.
Gurewich V. Gurewich V. JAMA. 2005 Feb 9;293(6):736-9. doi: 10.1001/jama.293.6.736. JAMA. 2005. PMID: 15701916 No abstract available.
Ximelagatran: an orally active direct thrombin inhibitor.
Gulseth MP. Gulseth MP. Am J Health Syst Pharm. 2005 Jul 15;62(14):1451-67. doi: 10.2146/ajhp040534. Am J Health Syst Pharm. 2005. PMID: 15998925 Review.
PURPOSE: The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects of ximelagatran are reviewed. SUMMARY: Ximelagatran is the first orally active direct thrombin inhibitor to be tested in Phas …
PURPOSE: The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, contraindications, and adverse effects …
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC, Perry CM, Faulds D. Evans HC, et al. Drugs. 2004;64(6):649-78. doi: 10.2165/00003495-200464060-00010. Drugs. 2004. PMID: 15018597 Review.
The efficacy of subcutaneous melagatran followed by oral ximelagatran has been investigated in four European trials and the efficacy of an all oral ximelagatran regimen has been investigated in five US trials. ...However, ximelagatran 36 mg twice daily was su …
The efficacy of subcutaneous melagatran followed by oral ximelagatran has been investigated in four European trials and the efficacy …
610 results